116 related articles for article (PubMed ID: 9163728)
1. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
2. Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines.
Choi CH; Kim HS; Rha HS; Jeong JH; Park YH; Min YD; Kee KH; Lim DY
Mol Cells; 1999 Jun; 9(3):314-9. PubMed ID: 10420992
[TBL] [Abstract][Full Text] [Related]
3. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
5. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Choi CH; Kang G; Min YD
Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.
Kim WJ; Kakehi Y; Hirai M; Arao S; Hiai H; Fukumoto M; Yoshida O
Jpn J Cancer Res; 1995 Oct; 86(10):969-77. PubMed ID: 7493917
[TBL] [Abstract][Full Text] [Related]
10. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
Choi CH; Kim HS; Kweon OS; Lee TB; You HJ; Rha HS; Jeong JH; Lim DY; Min YD; Kim MS; Chung MH
Mol Cells; 2000 Feb; 10(1):38-46. PubMed ID: 10774745
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
14. A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia.
Hedley DW; Xie SX; Minden MD; Choi CH; Chen H; Ling V
Leukemia; 1997 Jan; 11(1):48-53. PubMed ID: 9001418
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole SP; Sparks KE; Fraser K; Loe DW; Grant CE; Wilson GM; Deeley RG
Cancer Res; 1994 Nov; 54(22):5902-10. PubMed ID: 7954421
[TBL] [Abstract][Full Text] [Related]
16. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line.
Hu XF; Slater A; Wall DM; Kantharidis P; Parkin JD; Cowman A; Zalcberg JR
Br J Cancer; 1995 May; 71(5):931-6. PubMed ID: 7734315
[TBL] [Abstract][Full Text] [Related]
17. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
19. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
20. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells.
Slapak CA; Mizunuma N; Kufe DW
Blood; 1994 Nov; 84(9):3113-21. PubMed ID: 7949184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
